The Spartan RX is the first sample-to-result point-of-care DNA testing system. The CYP2C19 test kit identifies carriers of the CYP2C19*2 allele.
30% of the population carries the *2 allele.1 This results in decreased activation of drugs such as Plavix® (clopidogrel).
*2 carriers have a 42% higher risk of death, stroke, or second heart attack after cardiac stenting and starting Plavix®.2
For *2 carriers, 40%–50% of Major Adverse Cardiac Events (MACE) occur within the first 24–48 hours.2,3
The Spartan RX CYP2C19 system is fast, affordable, and reliable:
NOTE: This product is not available for sale in the United States.
1 Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.
2 Mega JL et al. (2009). N Engl J Med. 360:354–62.
3 Wiviott SD et al. (2007). N Engl J Med. 357:2001–2015.